Savant HWP Selected to Present at Cavendish Global Health Impact Forum

SAN CARLOS, Calif., April 10, 2014 /PRNewswire/ -- Savant HWP, a privately held pharmaceutical development company focused on unmet medical needs in addiction medicine and selected other global health issues, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place May 5-7 at the United Nations Headquarters in New York. 

"We are honored to be selected to present at this unique event, which is further recognition of Savant HWP's innovative approach to developing important medicines for significant but under-addressed health problems like drug addictions and Chagas disease," said Stephen L. Hurst, JD, Savant HWP President and Chief Executive Officer. "We welcome the chance to interact with many of world's leading scientific minds, thought-leaders and generous philanthropic individuals and families who are all dedicated to the common cause of improving the health and lives of people around the world."

The purpose of the Forum is to help family offices and foundations develop and implement their individual pro-social impact investing, grant-giving, and philanthropy programs within health and the life sciences.  To accomplish this mission the Forum showcases presentations and panel discussions by leading scientists, accomplished healthcare delivery professionals, health-policy experts and private-sector companies engaged in developing innovations with the potential for transformational impact on disease prevention, diagnosis and treatment. 

Michael Moffat, Cavendish co-founder and President explains, "With the help of our expert advisors, we conduct a global search of research institutions and private-sector companies in order to identify organizations that meet the required standard of excellence.  The quality and originality of Savant HWP's development programs positions them to make a major contribution to the treatment of many forms of drug addiction and abuse, as well as serious global health problems like Chagas disease, an important cause of congestive heart failure."

Cavendish Global consists of over 150 leading family offices and foundations from around the world with combined assets of over $190 billion who share a passion for pro-social endeavors within health and the life sciences.  The Cavendish Global Health Impact Forum provides family offices with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the information and educational resources required by foundations actively seeking to accelerate technological innovation and health access through sustainable philanthropy, grant-making and impact investing.  The Forum is also an opportunity for family offices to champion and share information on projects and organizations, which they are passionate about with other family offices from around the world.  Cavendish Global together with the Global Partnerships Forum and the New York Academy of Sciences organizes the Forum annually in New York.

About Cavendish Global

Cavendish Global provides family offices and their foundations with a discrete, peer-to-peer knowledge expansion and relationship building environment, combined with the innovative resources required to help develop and implement their individual pro-social impact investment, grant making and philanthropy programs within health and the life sciences. Cavendish Global provides family offices with a number of innovative resources, which includes Cavendish Impact Forums.  A unique gathering of leading family offices, Cavendish Impact Forums take place three times each year; in the United States (NYC, May 2014), Europe (London, October 2014) and a third event held at a Cavendish Host Partner City which moves to a different global location each year (Dubai, UAE January 2015).

For more information: http://cavendishglobal.com

About Savant HWP

Savant HWP, Inc., is a privately held pharmaceutical development company focused on unmet medical needs in addiction medicine and selected other global health issues including Chagas disease and Leishmaniasis. The company's lead program is focused on the development of 18-MC, a novel compound that targets the dopamine "reward" pathway in the brain that drives pleasure-seeking behaviors associated with addiction, obesity and many forms of compulsive behavior.

For more information on Savant HWP, please visit our website at http://www.savantHWP.com.

Logo - http://photos.prnewswire.com/prnh/20140410/SF01917LOGO

SOURCE Savant HWP, Inc.